Interní Med. 2010; 12(5): 252-259

faktory.

prof.MUDr.Vladimír Bláha, CSc., MUDr.Jakub Víšek, Ph.D.
Klinika gerontologická a metabolická, Fakultní nemocnice Hradec Králové

Současný výskyt hypertenze, diabetu, dyslipidemie a obezity je nově označován pojmem

kardiometabolické riziko. Dyslipidemie a hypertenze sdílejí některé společné patofyziologické

mechanizmy, které vedou k aterotrombóze a které jsou často také obdobné pro jiné kardiovaskulární



rizikové faktory: Společným jmenovatelem je zvýšená aktivita RAS (renin angiotenzin

systém), která má jednak důležitou úlohu v rámci hypertenze a jednak aktivuje podobně jako

dyslipidemie děje spojené s dysfunkcí endotelu, zánětem a trombózou. Zdá se, že statiny

mírně, nicméně signifikantně snižují krevní tlak u pacientů se zvýšeným (nikoliv normálním)

ambulantně monitorovaným krevním tlakem. V léčbě hypertenze spojené s dyslipidemií je

výběr vhodných antihypertenziv zásadním faktorem v ovlivnění kardiovaskulárního rizika

(dávka resp. kombinace farmak, zejména typu statinů a inhibitorů aktivace RAS).

Keywords: dyslipidemie, hypertenze, inhibitory RAS, statiny, kardiovaskulární rizikové

Published: June 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bláha V, Víšek J. faktory. Interní Med. 2010;12(5):252-259.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007, 49: 69-75. Go to original source... Go to PubMed...
    2. Belletti DA, Zacker Ch, Wogen J. Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States. Cardiovascular Diabetology 2010, 9:7. http://www.cardiab.com/content/9/1/7. Go to original source... Go to PubMed...
    3. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13: 3S-10S. Go to original source... Go to PubMed...
    4. Ong KL, Tso AWK, Lam KSL, Cheung BMY. Gender differences in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension 2008; 51: 1142-1148. Go to original source... Go to PubMed...
    5. Sullivan PW, Ghushchyan V, Wyatt HR, Hill JO. The medical cost of cardiometabolic risk factor clusters in the United States. Obesity 2007; 15: 3150-3158. Go to original source... Go to PubMed...
    6. Tu?ón J, Martín-Ventura JL, Blanco-Colio JM, et al. Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. Vascular Health and Risk Management 2007; 3(4): 521-526. Go to PubMed...
    7. Golomb BA, Ritchie JB, Criqui MH, Dimsdale JE. Statins lower blood pressure: results from the UCSD statin study. Circulation 2004; 110(Suppl. III): III-402.
    8. Poulter N, Sever PS. Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Circulation 2004; 110 (Suppl. III): III-402.
    9. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135. Go to original source... Go to PubMed...
    10. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-3095. Go to original source... Go to PubMed...
    11. Harrison DG, Venema RC, Arnal JF, et al. The endothelial cell nitric oxide synthase: is it really constitutively expressed? Agents Actions Suppl, 1995; 45: 107-117. Go to original source... Go to PubMed...
    12. Tuńón J, Egido J. Endothelial dysfunction, inflammation and statins: new evidences. Rev Esp Cardiol, 2004; 57: 903-905. Go to original source...
    13. Barnes PJ, Karin M. Nuclear factor-kappa B. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997; 336: 1066-1071. Go to original source... Go to PubMed...
    14. Riaz AA, Wang Y, Schramm R, et al. Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. FASEB J, 2004; 18: 881-883. Go to original source... Go to PubMed...
    15. Fliser D, Buchholz K, Haller H, et al. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107. Go to original source... Go to PubMed...
    16. Cipollone F, Fazia M, Iezzi A, et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004; 109: 1482-1488. Go to original source... Go to PubMed...
    17. Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 2005; 36: 1796-1800. Go to original source... Go to PubMed...
    18. Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004; 44: 362-368. Go to original source... Go to PubMed...
    19. Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105: 1756-1759. Go to original source... Go to PubMed...
    20. Koh KK, Chung WJ, Ahn JY, et al. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis 2004; 177: 155-160. Go to original source... Go to PubMed...
    21. Castelli WP, Anderson K. A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 1986; 80: 23-32. Go to original source... Go to PubMed...
    22. Gaziano JM, Sesso HD, Breslow JL, et al. Relation between systemic hypertension and blood lipids on the risk of myocardial infarction. Am J Cardiol. 1999; 84: 768-773. Go to original source... Go to PubMed...
    23. Halperin RO, Sesso DH, Ma Buring JE, et al. Dyslipidemia and the Risk of Incident Hypertension in Men. Hypertension 2006; 47; 45-50. Go to original source... Go to PubMed...
    24. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors of hypertension: the San Antonio Heart Study. Arch Intern Med. 1996; 156: 1994-2000. Go to original source...
    25. Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension 1991; 17: 969-976. Go to original source... Go to PubMed...
    26. Golomb BA, Ritchie JB, Criqui MH, Dimsdale JE. Statins lower blood pressure: results from the UCSD statin study. Circulation 2004; 110(Suppl. III): III-402.
    27. Koh KK, Quon MJ, Waclawiw MA. Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis 2008; 196: 1-8. Go to original source... Go to PubMed...
    28. Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549-555. Go to original source... Go to PubMed...
    29. Borghi C, Dormi A, Veronesi M, et al. Brisighella Heart Study Working Party Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004; 148: 285-292. Go to original source... Go to PubMed...
    30. Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83(1497-1499): A8. Go to original source... Go to PubMed...
    31. Magen E, Viskoper R, Mishal J, et al. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J 2004; 6: 742-746.
    32. Terzoli L, Mircoli L, Raco R, Ferrari AU. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol 2005; 46: 310-315. Go to original source... Go to PubMed...
    33. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007, 49: 69-75. Go to original source... Go to PubMed...
    34. Belletti DA, Zacker Ch, Wogen J. Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States. Cardiovascular Diabetology 2010, 9:7. http://www.cardiab.com/content/9/1/7. Go to original source... Go to PubMed...
    35. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13: 3S-10S. Go to original source... Go to PubMed...
    36. Ong KL, Tso AWK, Lam KSL, Cheung BMY. Gender differences in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension 2008; 51: 1142-1148. Go to original source... Go to PubMed...
    37. Sullivan PW, Ghushchyan V, Wyatt HR, Hill JO. The medical cost of cardiometabolic risk factor clusters in the United States. Obesity 2007; 15: 3150-3158. Go to original source... Go to PubMed...
    38. Tu?ón J, Martín-Ventura JL, Blanco-Colio JM, et al. Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. Vascular Health and Risk Management 2007; 3(4): 521-526. Go to PubMed...
    39. Golomb BA, Ritchie JB, Criqui MH, Dimsdale JE. Statins lower blood pressure: results from the UCSD statin study. Circulation 2004; 110(Suppl. III): III-402.
    40. Poulter N, Sever PS. Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Circulation 2004; 110 (Suppl. III): III-402.
    41. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135. Go to original source... Go to PubMed...
    42. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-3095. Go to original source... Go to PubMed...
    43. Harrison DG, Venema RC, Arnal JF, et al. The endothelial cell nitric oxide synthase: is it really constitutively expressed? Agents Actions Suppl, 1995; 45: 107-117. Go to original source... Go to PubMed...
    44. Tuńón J, Egido J. Endothelial dysfunction, inflammation and statins: new evidences. Rev Esp Cardiol, 2004; 57: 903-905. Go to original source...
    45. Barnes PJ, Karin M. Nuclear factor-kappa B. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997; 336: 1066-1071. Go to original source... Go to PubMed...
    46. Riaz AA, Wang Y, Schramm R, et al. Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. FASEB J, 2004; 18: 881-883. Go to original source... Go to PubMed...
    47. Fliser D, Buchholz K, Haller H, et al. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107. Go to original source... Go to PubMed...
    48. Cipollone F, Fazia M, Iezzi A, et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004; 109: 1482-1488. Go to original source... Go to PubMed...
    49. Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 2005; 36: 1796-1800. Go to original source... Go to PubMed...
    50. Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004; 44: 362-368. Go to original source... Go to PubMed...
    51. Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105: 1756-1759. Go to original source... Go to PubMed...
    52. Koh KK, Chung WJ, Ahn JY, et al. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis 2004; 177: 155-160. Go to original source... Go to PubMed...
    53. Castelli WP, Anderson K. A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 1986; 80: 23-32. Go to original source... Go to PubMed...
    54. Gaziano JM, Sesso HD, Breslow JL, et al. Relation between systemic hypertension and blood lipids on the risk of myocardial infarction. Am J Cardiol. 1999; 84: 768-773. Go to original source... Go to PubMed...
    55. Halperin RO, Sesso DH, Ma Buring JE, et al. Dyslipidemia and the Risk of Incident Hypertension in Men. Hypertension 2006; 47; 45-50. Go to original source... Go to PubMed...
    56. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors of hypertension: the San Antonio Heart Study. Arch Intern Med. 1996; 156: 1994-2000. Go to original source...
    57. Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension 1991; 17: 969-976. Go to original source... Go to PubMed...
    58. Golomb BA, Ritchie JB, Criqui MH, Dimsdale JE. Statins lower blood pressure: results from the UCSD statin study. Circulation 2004; 110(Suppl. III): III-402.
    59. Koh KK, Quon MJ, Waclawiw MA. Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis 2008; 196: 1-8. Go to original source... Go to PubMed...
    60. Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549-555. Go to original source... Go to PubMed...
    61. Borghi C, Dormi A, Veronesi M, et al. Brisighella Heart Study Working Party Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004; 148: 285-292. Go to original source... Go to PubMed...
    62. Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83(1497-1499): A8. Go to original source... Go to PubMed...
    63. Magen E, Viskoper R, Mishal J, et al. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J 2004; 6: 742-746.
    64. Terzoli L, Mircoli L, Raco R, Ferrari AU. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol 2005; 46: 310-315. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.